Strategies for improving the clinical efficacy of photodynamic therapy (PDT) in treatment of solid cancers include applications of different types of adjuvant treatments in addition to this modality that may result in superior therapeutic outcome. Examples of such an approach investigated using mouse ...
Biohazardous waste is also divided into two primary categories: solid and liquid biohazardous waste. The difference between liquid waste and solid biohazardous waste is thus defined: liquid waste comprises any type of liquid drained or generated from an infected area of the body (animal or human)...
Two years later, a fast, low-budget, and scalable oil–water interfacial self-assembly process for preparing oriented Ag nanowire (AgNW) films on a solid base was reported [93]. Compared with the conventional LB process, this technique had a simpler operation and did not require pretreatment ...
10.7554/eLife.10250.001Cancer-associated fibroblasts (CAFs) are a major cellular component of tumor microenvironment in most solid cancers. Altered cellula... H Zhao,L Yang,B Joelle,... - eLife,5,(2016-02-26) 被引量: 141发表: 2016年 Genome-wide association study identifies novel loci associa...
NOS2 was first isolated from macrophages and expressed only following induction by inflammatory mediators such as tumor necrosis factor α (TNFα, interferons type II (IFN-γ), interleukin family (IL family: IL-1, IL-1β, IL-2, IL-10), lipopolysaccharide/endotoxin (LPS) [53,54]. The ...
Constant exposure to the Sun’s ultraviolet radiation induces most of theskinchanges commonly associated with aging, such as wrinkling, thickening, and changes in pigmentation. There is also a much higherfrequencyofskin cancer, particularly in persons with fair skin. The three basic skin cancers, ...
» WBC counts between 50,000 and 100,000 /µL of blood- Severe infection/ solid tumor or organ rejection and blood cultures are required to establish the serious bacterial infections. » White blood cell (WBC) count >100,000 /µL of blood- Leukemia/ blood cancers or bone marrow ca...
In addition, we discuss the anti-tumor potential of novel non-approved molecules and antibodies able to target some of the aforementioned GPCRs in different experimental models and clinical trials. Likewise, we focus on the repurposing in cancer patients of non-oncological GPCR-based drugs, ...